ADVANCING MOST-FAVORED-NATION (MFN) PRICING: President Donald J. Trump has unveiled the 17th agreement with Regeneron, a leading pharmaceutical manufacturer, aimed at reducing prescription drug prices in the United States. This initiative aligns with the lowest prices paid by developed nations, known as the most-favored-nation (MFN) pricing.
- This agreement grants all State Medicaid programs access to MFN drug prices for new Regeneron products, promising significant savings and bolstering efforts to support vulnerable Americans.
- It also prevents foreign nations from leveraging price controls to benefit from American innovation by ensuring MFN pricing for all new drugs from Regeneron.
- Regeneron is required to return increased foreign revenues from existing products, benefiting American patients as part of the President’s America First trade policies.
- This marks the 17th MFN deal under the President’s administration, covering 17 top pharmaceutical manufacturers and representing 86% of the branded drug market. Each manufacturer is committed to rebalancing international drug pricing for American patients.
DELIVERING LOWER COSTS: Patients will experience substantial price cuts on medications purchased directly via TrumpRx due to these measures.
- Regeneron will lower the price of its cholesterol drug, Praluent, from $537 to $225 for those buying through TrumpRx.
- All forthcoming Regeneron medications will also be priced at MFN levels for U.S. patients.
GROUNDBREAKING RARE DISEASE TREATMENT AT NO COST: The President announced that Regeneron’s new gene therapy for a rare genetic deafness, Otarmeni, will be provided free of charge to U.S. patients as part of this agreement.
- Otarmeni received approval today through the FDA Commissioner’s National Priority Voucher Program, a new process for expediting the review of products that meet vital national priorities.
- This essential treatment will be available at no cost to American families eager for their children to hear.
INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS: Regeneron has announced plans to invest $27 billion in U.S. research, development, and manufacturing by 2029.
- The company intends to more than double its manufacturing capacity in the United States to produce biologic pharmaceutical medicines for domestic distribution.
- This investment contributes to a total of $448 billion in U.S. pharmaceutical investments under President Trump in just 15 months.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is fulfilling promises to American patients, achieving historic victories that were once deemed impossible by the political establishment.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing actions to align American drug prices with those of similar nations.
- On July 31, 2025, President Trump sent letters to 17 leading pharmaceutical manufacturers, detailing steps to reduce U.S. prescription drug prices to match the lowest in other developed nations. MFN deals are now in place with each of these manufacturers.
- On September 30, 2025, President Trump announced the first agreement with Pfizer to provide MFN prices to American patients.
- On December 1, 2025, the U.S. government announced an agreement with the U.K. to increase the net price of new prescription drugs by 25% in the U.K., ensuring they contribute fairly to innovative medicines.
- On December 19, 2025, President Trump announced nine new agreements with major pharmaceutical companies.
- On February 5, 2026, President Trump launched TrumpRx.gov, allowing patients access to substantial discounts on many popular and high-priced medicines, in line with MFN pricing.
- As of April 23, the Administration has agreements with Pfizer, Astra Zeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and Regeneron.
